Probiotics are live microbial organisms that are present in foods or dietary supplements and that confer health benefits to the host when ingested in sufficient quantities. Probiotics can be bacterial (e.g. Bifidobacteria spp. and Lactobacillus spp.) or yeasts (e.g. Saccharomyces boulardii). The administration of probiotics is often believed to be by and large beneficial for individuals with inflammatory or infectious diseases of the gastrointestinal tract. These positive effects are generally attributed to the ability of probiotics to regulate intestinal permeability, normalize host intestinal flora, improve gut immune barrier function, and equilibrate the balance between proinflammatory and anti-inflammatory cytokines. Of note, however, these claims are not always substantiated by findings from properly conducted clinical trials. Of particular importance, even when results from randomized controlled trials support the beneficial effects of a particular probiotic for a specific indication, the benefits achieved by the probiotic are generally not translatable to other probiotic formulations. This review discusses the gastrointestinal indications for probiotic use and describes the level of evidence that supports the use of specific probiotics for these indications. Several indications are addressed, including enteric infections, gastritis caused by Helicobacter pylori infection, necrotizing enterocolitis, inflammatory bowel diseases, and irritable bowel syndrome.

Keywords:
Inflammatory bowel disease, Irritable bowel syndrome, Helicobacter pylori, Probiotics, Gastrointestinal, Diarrhea, Clostridium, Necrotizing enterocolitis
1.
Isolauri E, et al: Modulation of the maturing gut barrier and microbiota: a novel target in allergic disease. Curr Pharm Des 2008;14:1368–1375.
2.
Hatakka K, Saxelin M: Probiotics in intestinal and non-intestinal infectious diseases – clinical evidence. Curr Pharm Des 2008;14:1351–1367.
3.
Pochart P, et al: Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 1992;55:78–80.
4.
Marteau P, et al: Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003;17:725–740.
5.
Bouhnik Y, et al: Fecal recovery in humans of viable Bifidobacterium sp ingested in fermented milk. Gastroenterology 1992;102:875–878.
6.
Boirivant M, et al: The mechanism of action of probiotics. Curr Opin Gastroenterol 2007;23:679–692.
7.
Sherman PM, et al: Unraveling mechanisms of action of probiotics. Nutr Clin Pract 2009;24:10–14.
8.
Candela M, et al: Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol 2008;125:286–292.
9.
Gedek BR: Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 1999;42:261–264.
10.
Elmer GW, McFarland LV: Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother 1987;31:129–131.
11.
Tasteyre A, et al: Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathog 2002;32:219–225.
12.
Pothoulakis C, et al: Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993;104:1108–1115.
13.
Castagliuolo I, et al: Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999;67:302–307.
14.
Brotz H, et al: Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 1998;30:317–327.
15.
Mattar AF, et al: Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 2002;18:586–590.
16.
Madsen K, et al: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580–591.
17.
Macpherson AJ, et al: A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 2000;288:2222–2226.
18.
Qamar, et al: Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001;69:251–256.
19.
Matsuzaki T, Chin J: Modulating immune responses with probiotic bacteria. Immunol Cell Biol 2000;78:67–73.
20.
Borchers AT, et al: Probiotics and immunity. J Gastroenterol 2009;44:26–46.
21.
Delcenserie V, et al: Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008;10:37–54.
22.
Lopez AD, et al: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;67:1747–1757.
23.
Majamaa H, et al: Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995;20:333–338.
24.
Shornikova AV, et al: Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997;24:399–404.
25.
Salazar-Lindo E, et al: Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]. BMC Pediatr 2004;4:18.
26.
Henker J, et al: The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007;166:311–318.
27.
Costa-Ribeiro H, et al: Limitations of probiotic therapy in acute, severe dehydrating diarrhea. J Pediatr Gastroenterol Nutr 2003; 36:112–115.
28.
Canani RB, et al: Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007;335:340–345.
29.
Szajewska H, et al: Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007;25:257–264.
30.
Szajewska H, et al: Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007;25:871–881.
31.
Guarino A, et al: The ESPGHAN/ESPID evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr 2008;46(suppl 2):S81–S122.
32.
Szajewska H, et al: Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001;138:361–365.
33.
Mastretta E, et al: Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. J Pediatr Gastroenterol Nutr 2002;35:527–531.
34.
Saavedra JM, et al: Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;344:1046–1049.
35.
Wunderlich PF, et al: Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res 1989;17:333–338.
36.
Buydens P, et al: Efficacy of SF 68 in the treatment of acute diarrhea. A placebo-controlled trial. Scand J Gastroenterol 1996;31:887–891.
37.
Pereg D, et al: The effect of fermented yogurt on the prevention of diarrhea in a healthy adult population. Am J Infect Control 2005;33:122–125.
38.
Clements ML, et al: Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. Antimicrob Agents Chemother 1981;20:104–108.
39.
Sazawal S, et al: Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006;6:374–382.
40.
Turck D, et al: Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 2003;37:22–26.
41.
McFarland LV: Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998;16:292–307.
42.
Asha NJ, et al: Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 2006;44:2785–2791.
43.
Spencer RC: Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 1998;41(suppl C):5–12.
44.
Buts JP, De Keyser N: Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 2006;51:1485–1492.
45.
Arvola T, et al: Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999;104:e64.
46.
Vanderhoof JA, et al: Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999;135:564–568.
47.
Hickson M, et al: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335:80.
48.
Surawicz CM, et al: Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981–988.
49.
McFarland LV, et al: Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439–448.
50.
Kotowska M, et al: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005;21:583–590.
51.
Szajewska H, Mrukowicz J: Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic associated diarrhoea. Aliment Pharmacol Ther 2005;22:365–372.
52.
Johnson BC, et al: Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2007;2: CD004827.
53.
McFarland LV: Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812–822.
54.
Kale-Pradhan PB, et al: Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: a meta-analysis. Pharmacotherapy 2010;30:119–126.
55.
Ricciardi R, et al: Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007;142:624–631.
56.
Byrn JC, et al: Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008;143:150–154.
57.
Qamar A, et al: Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001;69:2762–2765.
58.
Pillai A, Nelson R: Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008;1:CD004611.
59.
McFarland LV, et al: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913–1918.
60.
Surawicz C, et al: The search for a better treatment for recurrent Clostridium difficile disease: use of high dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012–1027.
61.
Wullt M, et al: Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003;35:365–367.
62.
McFarland LV: Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 2007;5:97–105.
63.
Black FT, et al: Prophylactic efficacy of lactobacilli on traveler’s diarrhea. Travel Med 1989;7:333–335.
64.
Briand V, et al: Absence of efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler’s diarrhea: a randomized, double-blind, controlled study. Clin Infect Dis 2006;43:1170–1175.
65.
Hilton E, Kolakowski P, Singer C, et al: Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med 1997;4:41–43.
66.
Kollaritsch H, et al: Prevention of traveler’s diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Fortschr Med 1993;111:152–156.
67.
Gronlund MM, et al: Fecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after cesarean delivery. J Pediatr Gastroenterol Nutr 1999;28:19–25.
68.
Kero J, et al: Mode of delivery and asthma – is there a connection? Pediatr Res 2002;52:6–11.
69.
Salminen S, et al: Influence of mode of delivery on gut microbiota composition in seven year old children. Gut 2004;53:1388–1389.
70.
Gaul J: Probiotics for the prevention of necrotizing enterocolitis. Neonatal Netw 2008;27:75–80.
71.
Barclay AR, et al: Probiotics for necrotizing enterocolitis: a systematic review. J Pediatr Gastroenterol Nutr 2007;45:569–576.
72.
Agostini C, et al: Probiotic bacteria in dietetic products for infants: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2004;38:365–374.
73.
Stratiki Z, et al: The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants. Early Hum Dev 2007;83:575–579.
74.
Lin HC, et al: Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008;122:693–700.
75.
Bin-Nun A, et al: Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005;147:192–196.
76.
Deshpande G, et al: Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010;125:921–930.
77.
Felley CP, et al: Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001;13:25–29.
78.
Canducci F, et al: A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000;14:1625–1629.
79.
Sykora J, et al: Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol 2005;39:692–698.
80.
Szajewska H, et al: Randomized, double-blind, placebo-controlled trial: effect of Lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr 2009;48:431–436.
81.
Cindoruk M, et al: Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007;12:309–316.
82.
Tong JL, et al: Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155–168.
83.
Zou J, et al: Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009;14:97–107.
84.
Sokol H, et al: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731–16736.
85.
Frick JS, et al: Identification of commensal bacterial strains that modulate Yersinia enterocolitica and dextran sodium sulfate-induced inflammatory responses: implications for the development of probiotics. Infect Immun 2007;75:3490–3497.
86.
Fitzpatrick LR, et al: Effects of the probiotic formulation VSL#3 on colitis in weanling rats. J Pediatr Gastroenterol Nutr 2007;44:561–570.
87.
Gionchetti P, et al: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202–1209.
88.
Gionchetti P, et al: High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007;50:2075–2082.
89.
Shen B, et al: Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005;22:721–728.
90.
Elahi B, et al: On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008;53:1278–1284.
91.
Kato K, et al: Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20:1133–1141.
92.
Zocco MA, et al: Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567–1574.
93.
Bibiloni R, et al: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539–1546.
94.
Sood A, et al: The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1202–1209.
95.
Sang LX, et al: Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol 2010;16:1908–1915.
96.
Marteau P, et al: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55:842–847.
97.
Van Gossum A, et al: Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm Bowel Dis 2007;13:135–142.
98.
Chermesh I, et al: Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn’s disease. Dig Dis Sci 2007;52:385–389.
99.
Rolfe VE, et al: Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2006;4:CD004826.
100.
Rahimi R, et al: A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig Dis Sci 2008;53:2524–2531.
101.
Ait-Belgnaoui A, et al: Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 2006;55:1090–1094.
102.
O’Mahony L, et al: Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541–551.
103.
Whorwell PJ, et al: Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581–1590.
104.
Guyonnet D, et al: Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26:475–486.
105.
Niv E, et al: The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome – a double blind, placebo-controlled, randomized study. Clin Nutr 2005;24:925–931.
106.
Niedzielin K, et al: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143–1147.
107.
Nobaek S, et al: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231–1238.
108.
Ligaarden SC, et al: A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 2010;10:16.
109.
Halpern GM, et al: Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996;91:1579–1585.
110.
Sinn DH, et al: Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008;53:2714–2718.
111.
O’Sullivan MA, et al: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000;32:294–301.
112.
Bausserman M, et al: The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005;147:197–201.
113.
Gawrońska A, et al: A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:177–184.
114.
Hun L, et al: Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009;121:119–124.
115.
Dolin BJ: Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009;31:655–659.
116.
Kim HJ, et al: A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687–696.
117.
Enck P, et al: A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome – a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008;20:1103–1109.
118.
Kajander K, et al: Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008;27:48–57.
119.
McFarland LV, et al: Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14:2650–2661.
120.
Moayyedi P, et al: The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325–332.
121.
Borriello SP, et al: Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003;36:775–780.
122.
LPSN: List of Prokaryotic Names with Standing in Nomenclature. http://www.bacterio.cict.fr/index.html (accessed August 26, 2010).
123.
Oxford Centre for Evidence-Based Medicine Levels of Evidence http://www.cebm.net/index.aspx?o=1025 (accessed August 26, 2010).
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.